We have identified naturally occurring 2-benzylidenebenzofuran-3-ones (aurones) as new templates for non-nucleoside hepatitis C virus (HCV) RNA-dependent RNA polymerase Their potent RdRp inhibitory activity, together with their low toxicity, make these molecules attractive candidate direct-acting anti-HCV agents.
Introduction

Hepatitis C virus (HCV) infection is a global public health problem. The World Health
Organisation (WHO) estimates that 120-140 million people are infected worldwide (2-3% of the world population), while 3-4 million are newly infected each year. Chronic HCV infection is associated with chronic liver inflammation and fibrosis. In the absence of antiviral treatment, HCV liver disease progresses to cirrhosis in 20-30% of chronically infected patients, and patients with cirrhosis have a 1% to 4% annual risk of developing hepatocellular carcinoma. 1 HCV infection is curable. The current standard of care is a combination of pegylated interferon alpha (peg-IFN) and ribavirin (RBV). [2] [3] [4] [5] Unfortunately, the response rate is low, especially among patients infected by HCV genotype 1, the most frequent genotype in the U.S., Europe, Asia, and Latin America (60 to 75% of cases). 6 In 2012, a new treatment based on a combination of peg-IFN, ribavirin and a direct-acting antiviral drug that inhibits HCV serine protease activity (telaprevir or boceprevir) will be available for patients with HCV genotype 1 infection. Yet these new therapies will fail in 20-30% of treatment-naïve patients and in about 50% of patients in whom a first course of peg-IFN and ribavirin has failed to eradicate the infection. Thus, as a preventive vaccine will not be available for several years, there is an urgent need for more effective anti-HCV drugs.
The HCV RNA-dependent RNA polymerase (RdRp) is a particularly attractive target because of its key role in viral replication and the fact that this enzyme has no functional equivalent in mammalian cells, thus ensuring its selectivity. A number of HCV RdRp inhibitors have been identified, including nucleoside/nucleotide analogues that target the active site, and non-nucleoside allosteric inhibitors. 7, 8 The HCV RdRp structure resembles a right hand. Four allosteric binding sites have been identified so far, including "Thumb"
Pockets I and II and "Palm" Pockets I and II. 8, 9 To date, two classes of molecules sharing a number of similarities have been reported to bind to Thumb Pocket I, including 2-aryl-1-
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affected by the other amino acid substitutions. The inhibitory activity of aurone 11 was therefore only affected by the P495L substitution, indirectly suggesting that this compound binds to (or close to) Thumb Pocket I.
We used the findings reported in Table 1 and mutagenesis experiments to examine the structure-activity relationship of aurones. Various substituents were used to determine the influence of physico-chemical parameters, including hydrogen bond donor potential, electronegativity, sterical effects and lipophilicity. Molecular docking was used throughout the decision process to identify the relevant substituents and their positions. The results are shown in Table 2 . The presence of a hydroxyl group at position 4 appeared to be crucial.
Replacement of the catechol moiety (B-ring) of 1 with a resorcinol in 34 did not affect inhibitory potency. Deletion of one of the B-ring hydroxyl groups of 34 yielded the less active derivative 12, while suppression of both B-ring hydroxyl groups led to even less active aurones. Table 2 also indicates that the presence of two hydroxyl groups, at positions 4 and 6, instead of only one at position 4, slightly increased the activity.
Based on the reported X-ray crystallographic structure of genotype 1b HCV RdRp complexed with a tetracyclic indole-based inhibitor binding to Thumb Pocket I (PDB ID: 2dxs), 29 docking calculations were used to rationalize the observed activities. The best poses generated with Autodock software for compound 1 showed that Arginine 503 anchored the molecule, forming two hydrogen bonds with the 4-hydroxyl group and the ketone of the aurone. Glycine 493 allowed the formation of a third hydrogen bond with the 6-hydroxy group. These findings potentially explained the slightly better activities of 4,6-dihydroxyaurones compared with 4-hydroxyaurones. At the B-ring, the 3'-and 4'-hydroxyl groups of 1 allowed the formation of two additional chelating hydrogen bonds with the carbonyl group of Leucine 392 inside the hydrophobic pocket, as shown in Figure 4A . These findings explain the strong impact of hydroxy groups at these positions.
Replacement of the 4'-hydroxyl group by its isosteric, fluorine atom led to the slightly less active derivative 42, suggesting that hydrogen bonding plays a minor role in this region of the inhibitor. The introduction of methoxy groups instead of hydroxy groups at the B-ring led to compounds with similar (compounds 24, 35) or weaker (compounds 26, 36) activities, indicating that, in some cases, the insertion of more hydrophobic and bulky substituents is well tolerated. Conversely, methoxylation of the hydroxyl groups at the A-ring, or replacement of these groups by fluoro substituents, led to a marked fall in inhibitory activity (compounds 13, 20, 47, 48).
Given the strongly hydrophobic environment of Thumb Pocket I and the results of our
initial docking studies, we tested the effect of adding hydrophobic substituents at the B-ring, especially at position 4', on interactions with the pocket. The introduction of methyl and ethyl groups at the B-ring resulted in better inhibitory activity (compounds 23 and 37). Thus, alkyl substituents were grafted at position 4'. The introduction of a n-butyl or a cyclohexyl group provided the best inhibitory activity (compounds 39 and 40), indicating that both highly lipophilic and bulky substituents at the C-4' position were associated with the strongest activities.
Overall, we identified the following pharmacophoric elements as crucial in the inhibitory activity of aurones on HCV RdRp: a) a hydroxyl group at position 4, or a dihydroxyl group at positions 4 and 6; and b) a hydrophobic and bulky substituent at position 4' of the B-ring. We also found that replacement of the cyclohexyl by a 4-methylpiperazine in 31 was tolerated. Molecular docking of aurones 39 and 40, based on the known crystallographic structure of genotype 1b HCV RdRp complexed with a tetracyclic indolebased inhibitor binding to Thumb Pocket I (PDB ID: 2dxs), 29 showed strong fitting of the 4'-n-butyl and 4'-cyclohexyl moieties into the pocket. Further virtual docking screening inserm-00618322, version 1 -1 Sep 2011
suggested that aurone analogues in which the B-ring is replaced by a substituted indole moiety are potential ligands.
In models built with GOLD and Autodock software, the best poses were obtained for Figure 4B . These findings validated the docking results and confirmed the inhibitory potential of this group of indole derivatives.
Overall, the results obtained with weak inhibitors were, as expected, difficult to interpret, but the geometries of poses obtained with more efficient compounds were homogeneous and relevant. The strong activities of both 4'-hydroxyl and 4'-hydrophobic compounds could be explained by the good fit of these two subclasses of aurones in the pocket. Compounds 1 and 51 were representative of the hypothetic dual mode of aurone binding to Thumb Pocket I of HCV RdRp.
All the reported compounds were evaluated for cytotoxicity, based on the MTT assay with two human cell lines (HuH7 and HEK293) (data not shown). No cell death was observed at effective concentrations.
Conclusion
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mixture was concentrated under reduced pressure, then the residue was diluted in water (50 mL/mmol), and an aqueous solution of hydrochloric acid (1N) was added to adjust the pH to 2-3. The mixture was extracted with ethyl acetate or dichloromethane and washed with water and brine. The combined organic layers were dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure to give the crude compound.
General procedure B for the preparation of (Z)-2-benzylidenebenzofuran-3(2H)-one derivatives. To a solution of a benzofuran-3(2H)-one derivative in ethanol (4 mL/mmol)
were added an aqueous solution of potassium hydroxide (50%, 5 mL/mmol) and a benzaldehyde derivative (2 equivalents). The solution was then refluxed until TLC showed complete disappearance of the starting materials (2 to 5 hours). After cooling, the mixture was concentrated under reduced pressure, then the residue was diluted in water (50 mL/mmol),
and an aqueous solution of hydrochloric acid (1N) was added to adjust the pH to 2-3. The mixture was extracted with ethyl acetate or dichloromethane and washed with water and brine. The combined organic layers were dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure to give the crude compound. 
(Z)-2-(3-hydroxybenzylidene)-4-hydroxybenzofuran-3(2H)-one (15).
The crude product was prepared according to general procedure A starting from 4-hydroxybenzofuran-3(2H)-one (5) and 3-hydroxybenzaldehyde, and was recrystallized from acetonitrile to yield pure yellow crystals (55% 
(Z)-2-(2,4-dimethoxybenzylidene)-4-hydroxybenzofuran-3(2H)-one (24
(Z)-2-(4-(4-methylpiperazin-1-yl)benzylidene)-4-hydroxybenzofuran-3(2H)-one (31).
The crude product was prepared according to general procedure A starting from 4-hydroxybenzofuran-3(2H)-one (5) and 4-(4-methylpiperazin-1-yl)benzaldehyde, and was washed three times with distilled water to yield an orange solid, which was the analytically pure hydrochloride salt, used without further purification (71% 
(Z)-2-(2-fluorobenzylidene)-4-hydroxybenzofuran-3(2H)-one (32
(Z)-2-(2,4-dihydroxybenzylidene)-4,6-dihydroxybenzofuran-3(2H)-one (34). The crude product was prepared according to general procedure D starting from (Z)-2-(2,4-
dimethoxy-benzylidene)-4,6-dimethoxybenzo-furan-3(2H)-one (53), and was washed three times with distilled water to yield an orange solid, which was analytically pure and used without further purification (58%). m.p. > 270°C (decomposition). 1 Molecular Modeling. Docking studies used the reported X-ray crystallographic structure of HCV genotype 1b RdRp complexed with a known inhibitor binding to Thumb Pocket I of the enzyme (PDB ID: 2dxs). 29 The protein structure was extracted and water molecules were deleted. The complexed ligand was used to define the binding site for a homopolymeric RNA template (Poly U, GE Healthcare, Chalfont St. Giles, UK) and ATP, measured with an intercalating agent (SYBR® Green, Applied Biosystems), as previously described. 30 The Quick Site-Directed Mutagenesis kit (Stratagene, La Jolla, California) was used to assess the effect of amino acid substitutions conferring resistance to other specific HCV RdRp inhibitors. The tested substitutions included M423T, C316Y, H95Q, and P495L.
(Z)-2-(4-morpholinobenzylidene)-4,6-dihydroxybenzofuran-3(2H)-one (41)
The constructs were verified by DNA sequencing and the corresponding proteins were purified as described above. 
